Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: A review of the evidence

American Journal of Gastroenterology

Volumn 97, Issue 6, 2002, Pages 1319-1327

  Shaheen, Nicholas J ^a,c   Provenzale, Dawn ^b   Sandler, Robert S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISABILITY; EPIDEMIOLOGICAL DATA; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; POPULATION SURVEILLANCE;

EID: 0036084748     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04123-0     Document Type: Review

References (70)

1. National Cancer Data Base report on esophageal carcinoma
2. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study
3. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
4. Chronic peptic ulcer of the oesophagus and "oesophagitis."
5. Management of Barrett's esophagus
6. Barrett's esophagus: Pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management
7. Adenocarcinoma in Barrett's esophagus
8. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
9. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia
10. The Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
11. Symptomatic gastroesophageal reflux: Incidence and precipitating factors
12. Estimating benefits of screening from observational cohort studies
13. Evidence on screening for breast cancer from a randomized trial
14. Effects of lead time, length bias, and false-negative assurance on screening for breast cancer
15. En bloc resection for neoplasms of the esophagus and cardia
16. Cancer of the oesophagus. II. Therapy and outcome
17. Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia
18. Cancer of the esophagus. The Cleveland Clinic experience
19. Selective therapeutic approach to cancer of the lower esophagus and cardia
20. Cancer statistics, 2001
21. Epidemiology of columnar-lined esophagus and adenocarcinoma
22. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years
23. Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long-term results of a prospective study
24. Life expectancy and cancer risk in patients with Barrett's esophagus: A prospective controlled investigation
25. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy
26. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
27. The quality of care in Barrett's esophagus: Endoscopist and pathologist practices
28. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus
29. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy
30. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis
31. Barrett's esophagus: Prevalence and size of hiatal hernia
32. Association between body mass and adenocarcinoma of the esophagus and gastric cardia
33. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma
34. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma
35. Screening for Barrett's esophagus by balloon cytology
36. Unsedated smallcaliber esophagogastroduodenoscopy (EGD) versus conventional EGD: A comparative study
37. Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it costeffective?
38. Endoscopy in chronic heartburn to screen for Barrett's esophagus (BE): Can we really afford it?
39. Barrett's esophagus: Development of dysplasia and adenocarcinoma
40. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus
41. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma
42. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus
43. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry
44. Adenocarcinoma arising in Barrett's esophagus
45. Practice patterns for surveillance of Barrett's esophagus in the United States
46. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus
47. Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China
48. Autopsy findings in squamous-cell carcinoma of the esophagus
49. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
50. When should we stop screening?
51. Barrett's esophagus. Update of pathophysiology and management
52. Columnar mucosa and intestinal metaplasia of the esophagus: Fifty years of controversy
53. Occult esophageal adenocarcinoma: Extent of disease and implications for effective therapy
54. Longterm nonsurgical management of Barrett's esophagus with high-grade dysplasia
55. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation
56. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: Preliminary results
57. Adenocarcinoma and Barrett's esophagus. An overrated risk?
58. Adenocarcinoma in Barrett's oesophagus: An overrated risk
59. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study
60. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus
61. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus
62. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus
63. Screening for specialized columnar epithelium with methylene blue: Chromoendoscopy in patients with Barrett's esophagus and a normal control group
64. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
65. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?
66. Costeffectiveness of diagnostic strategies for patients with chest pain
67. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons
68. Evaluation of the dyspeptic patient: A cost-utility study